Vaxdyn, Seville, Spain
www.vaxdyn.com

KAPAVAX
TRIVALENT VACCINE TO PREVENT BACTERIAL PNEUMONIA
Vaccine

By leveraging its proprietary vaccine platform based on LPS-null Acinetobacter baumannii cells, Vaxdyn seeks to develop a single, trivalent vaccine directed against the Gram-negative pathogens A. baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae.  If successful, this vaccine could address significant unmet clinical need in preventing pneumonia in adults with elevated risk (e.g., patients with chronic lung disease or diabetes, or undergoing cancer treatment).  It also has the potential to prevent neonatal infections, an issue of critical importance, in particular in low-to-middle income countries around the world, by stimulating maternal immunity in pregnant women.

Current Development Stage: Pre-Clinical

CARB-X Investment: Initial investment of up to $892,000 with potential option payments up to $6.36m

Initial CARB-X Investment Date: June 1, 2019